Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Femasys ( (FEMY) ) has shared an announcement.
On August 6, 2025, Femasys Inc. announced its first commercial entry into Europe with a $400,000 order for FemBloc Permanent Birth Control in Spain, marking a strategic milestone in its global expansion. FemBloc, a revolutionary non-surgical permanent contraceptive, offers a less invasive and cost-effective alternative to traditional methods, and its introduction in Spain is supported by partnerships with Comercial Medico Quirúrgica and Durgalab. This development is expected to enhance Femasys’s market positioning and meet growing demand across Europe.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
Spark’s Take on FEMY Stock
According to Spark, TipRanks’ AI Analyst, FEMY is a Neutral.
Femasys’ financial performance is the most significant factor, with persistent losses and cash flow issues leading to a low score. Technical analysis shows bearish signals, and valuation metrics are poor due to negative earnings. Positive corporate events offer some hope, but regulatory compliance issues add risk.
To see Spark’s full report on FEMY stock, click here.
More about Femasys
Femasys Inc. is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide. The company offers a broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products, including FemaSeed Intratubal Insemination and FemVue for fallopian tube assessment. Femasys is actively commercializing its lead product innovations in the U.S. and key international markets.
Average Trading Volume: 298,017
Technical Sentiment Signal: Sell
Current Market Cap: $31.51M
Find detailed analytics on FEMY stock on TipRanks’ Stock Analysis page.